<DOC>
	<DOCNO>NCT02314442</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics ALN-PCSSC subject elevate LDL-C .</brief_summary>
	<brief_title>A Phase 1 Study Investigational Drug , ALN-PCSSC , Subjects With Elevated Low Density Lipoprotein Cholesterol ( LDL-C )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Adequate complete blood count , liver renal function Female subject must nonchildbearing potential ; e.g . postmenopausal premenopausal surgical sterilization Male subject agree use appropriate contraception Willing provide write informed consent willing comply study requirement . Nonsmokers nonnicotine user least 90 day screen On stable statin comedication [ designate multiple dose cohort ] Any uncontrolled serious disease , medical surgical condition , may interfere participation clinical study and/or put subject significant risk Received investigational agent within 90 day first dose study drug followup another clinical study History multiple drug allergy intolerance subcutaneous injection Received medication nutraceutical alter serum lipid within 30 day screen ( nonstatin cohort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>